Back to Authors

Chen, Zong-ming E.

Mayo Clinic

Mayo Clinic

Citations 2

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga
Thompson, Scott M. , Suman, Garima , Chen, Zongming E., Jondal, Danielle E. , Patra, Anurima , Ehman, Eric C. , Andrews, James C. , Fleming, Chad J. , Welch, Brian T. , Kurup, A. Nicholas , Roberts, Lewis R. , Watt, Kymberly D. , Truty, Mark J. , Smoot, Rory L. , Yin, Jun , Jacobson, Mark, Kemp, Bradley J. , Venkatesh, Sudhakar K. , Johnson, Geoffrey B. , Woodrum, David A. , Goenka, Ajit H. , Chen, Zong-ming E., Kurup, Anil N, Watt, K D , Cleary, Sean P. , Wang, Chen , Fogarty, Zachary C , Venkatesh, Sudhakar K , Roberts, Lewis R , Smoot, Rory L , Johnson, Geoffrey B , Kurup, Anil N , Thompson, Scott , Torbenson, Michael , Heimbach, Julie K. , Tran, Nguyen H. , Mahipal, Amit , Zemla, Tyler , Wang, Chen , Fogarty, Zachary C.

Hepatology Communications | November 16, 2021 | Volume: 6 | Issue: 5 | Pages: 1172-1185

10.1002/hep4.1861 Get It

Prostate‐specific membrane antigen (PSMA) is a validated target for molecular diagnostics and targeted radionuclide therapy. Our purpose was to evaluate PSMA expression in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and hepatic adenoma (HCA); investigate the genetic pathways in HCC associated with PSMA expression; and evaluate HCC detection rate with 68Ga‐PSMA‐11 positron emission tomography (PET). In phase 1, PSMA immunohistochemistry (IHC) on HCC (n = 148), CCA (n = 111), and HCA (n = 78) was scored. In a subset (n = 30), messenger RNA (mRNA) data from the Cancer Genome Atlas HCC RNA sequencing were correlated with PSMA expression. In phase 2, 68Ga‐PSMA‐11 PET was prospectively performed in patients with treatment‐naïve HCC on a digital PET scanner using cyclotron‐produced 68Ga. Uptake was graded qualitatively and semi‐quantitatively using standard metrics. On IHC, PSMA expression was significantly higher in HCC compared with CCA and HCA (P < 0.0001); 91% of HCCs (n = 134) expressed PSMA, which principally localized to tumor‐associated neovasculature. Higher tumor grade was associated with PSMA expression (P = 0.012) but there was no association with tumor size (P = 0.14), fibrosis (P = 0.35), cirrhosis (P = 0.74), hepatitis B virus (P = 0.31), or hepatitis C virus (P = 0.15). Overall survival tended to be longer in patients without versus with PSMA expression (median overall survival: 4.2 vs. 1.9 years; P = 0.273). FGF14 (fibroblast growth factor 14) mRNA expression correlated positively (rho = 0.70; P = 1.70 × 10‐5) and MAD1L1 (Mitotic spindle assembly checkpoint protein MAD1) correlated negatively with PSMA expression (rho = −0.753; P = 1.58 × 10‐6). Of the 190 patients who met the eligibility criteria, 31 patients with 39 HCC lesions completed PET; 64% (n = 25) lesions had pronounced 68Ga‐PSMA‐11 standardized uptake value: SUVmax (median [range] 9.2 [4.9‐28.4]), SUVmean 4.7 (2.4‐12.7), and tumor‐to‐liver background ratio 2 (1.1‐11). Conclusion: Ex vivo expression of PSMA in neovasculature of HCC translates to marked tumor avidity on 68Ga‐PSMA‐11 PET, which suggests that PSMA has the potential as a theranostic target in patients with HCC.
Dichotomous regulation of group 3 innate lymphoid cells by nongastric Helicobacter species
Bostick, John W. , Shen, Zeli , Ge, Yong, Brown, Jeffrey B. , Chen, Zong-ming E., Mohamadzadeh, Mansour , Fox, James G. , Zhou, Liang , Wang, Yetao , Ge, Yong

Proceedings of the National Academy of Sciences | November 18, 2019 | Volume: 116 | Issue: 49 | Pages: 24760-24769

10.1073/pnas.1908128116 Get It

Intestinal innate lymphoid cells (ILCs) contribute to the protective immunity and homeostasis of the gut, and the microbiota are critically involved in shaping ILC function. However, the role of the gut microbiota in regulating ILC development and maintenance still remains elusive. Here, we identified opposing effects on ILCs by two Helicobacter species, Helicobacter apodemus and Helicobacter typhlonius , isolated from immunocompromised mice. We demonstrated that the introduction of both Helicobacter species activated ILCs and induced gut inflammation; however, these Helicobacter species negatively regulated RORγt + group 3 ILCs (ILC3s), especially T-bet + ILC3s, and diminished their proliferative capacity. Thus, these findings underscore a previously unknown dichotomous regulation of ILC3s by Helicobacter species, and may serve as a model for further investigations to elucidate the host–microbe interactions that critically sustain the maintenance of intestinal ILC3s.